Caris Life Sciences (CAI) Stock Forecast & Price Target
Score
Caris Life Sciences, Inc. price target
| CAI | |
|---|---|
| Low | $22.00 |
| Average | $28.50 |
| High | $38.00 |
| Upside vs current price | +23.7% |
The average target of $28.50 is +23.7% versus the current CAI price of $23.04.
Caris Life Sciences, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 9 |
| Hold | 4 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
14 analysts cover CAI.
Caris Life Sciences, Inc. EPS and revenue estimates
The estimate table for the Caris Life Sciences, Inc. keeps 2026 EPS $0.12, 2027 EPS $0.35, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $0.12 | $1.03B |
| 2027 | $0.35 | $1.23B |
Is Caris Life Sciences, Inc. a buy or sell?
Of the 14 analysts covering Caris Life Sciences, Inc., 10 rate it a buy (1 strong buy and 9 buy), 4 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The CAI consensus label is Buy, beside 10 buy-side ratings and 0 sell-side ratings.
The average target of $28.50 implies +23.7% versus the current price of $23.04.
the Caris Life Sciences, Inc. closes with 10 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Caris Life Sciences, Inc. forecast
Analysts are far apart on CAI. The published low is $22.00, the average is $28.50, and the high is $38.00.
From today's $23.04 print, the CAI average target is +23.7% away.
Most of the CAI coverage agrees: 10 of 14 analysts are on the buy side, 4 are at hold, and 0 are on the sell side, and the published consensus is Buy.
CAI targets have been marked up: $38.00 across the last month versus $31.25 across the last quarter.
CAI coverage is thin at 14 analysts, and one revision moves the average.
Caris Life Sciences, Inc. forecast questions
What is the CAI price target?
The published range for CAI is $22.00 to $38.00, with an average of $28.50. That average is +23.7% versus the current price of $23.04.
Is Caris Life Sciences, Inc. a buy or sell?
Of the 14 analysts covering Caris Life Sciences, Inc., 10 rate it a buy, 4 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for CAI is 10 on the buy side, 4 at hold, and 0 on the sell side.
What is the EPS estimate for Caris Life Sciences, Inc.?
Analyst EPS estimates for Caris Life Sciences, Inc.: 2026 $0.12, 2027 $0.35.
What is the revenue estimate for Caris Life Sciences, Inc.?
Analyst revenue estimates for Caris Life Sciences, Inc.: 2026 $1.03B, 2027 $1.23B.
How many analysts cover CAI?
14 analysts cover CAI. Their consensus on CAI is Buy, across those 14.